See more : eClerx Services Limited (ECLERX.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Aptorum Group Limited (APM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aptorum Group Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Inmax Holding Co., Ltd. (1591.TWO) Income Statement Analysis – Financial Results
- Thermodynetics Inc. (TDYT) Income Statement Analysis – Financial Results
- Wataniya Insurance Company (8300.SR) Income Statement Analysis – Financial Results
- NCL International Logistics Public Company Limited (NCL.BK) Income Statement Analysis – Financial Results
- Medigene AG (0QGJ.L) Income Statement Analysis – Financial Results
Aptorum Group Limited (APM)
About Aptorum Group Limited
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 431.38K | 1.30M | 1.54M | 911.51K | 535.17K | 383.45K | 0.00 |
| Cost of Revenue | 420.81K | 1.22M | 1.46M | 1.02M | 794.55K | 318.01K | 58.90K |
| Gross Profit | 10.57K | 80.07K | 81.85K | -103.51K | -259.38K | 65.44K | -58.90K |
| Gross Profit Ratio | 2.45% | 6.18% | 5.31% | -11.36% | -48.47% | 17.07% | 0.00% |
| Research & Development | 5.20M | 9.22M | 10.87M | 11.59M | 6.94M | 3.10M | 2.50M |
| General & Administrative | 4.37M | 7.87M | 7.70M | 7.71M | 10.78M | 6.73M | 0.00 |
| Selling & Marketing | 48.98K | 98.08K | 95.95K | 55.43K | 0.00 | 0.00 | 0.00 |
| SG&A | 4.41M | 7.97M | 7.80M | 7.71M | 10.78M | 6.73M | 2.88M |
| Other Expenses | -9.60M | 404.54K | 623.64K | 877.39K | 220.89K | 560.71K | -257.18K |
| Operating Expenses | 10.57K | 17.59M | 19.29M | 20.17M | 17.94M | 10.39M | 5.63M |
| Cost & Expenses | 10.95M | 18.81M | 20.75M | 21.19M | 18.73M | 10.71M | 5.69M |
| Interest Income | 0.00 | 146.59K | 0.00 | 0.00 | 0.00 | 0.00 | 44.27K |
| Interest Expense | 121.15K | 146.59K | 93.60K | 243.63K | 3.70M | 4.46M | 0.00 |
| Depreciation & Amortization | 1.13M | 1.21M | 1.19M | 1.33M | 1.30M | 682.29K | 58.90K |
| EBITDA | -9.60M | -17.59M | -19.29M | 6.50M | -15.12M | -9.99M | -2.50M |
| EBITDA Ratio | -2,225.19% | -1,678.81% | -1,158.95% | -2,034.44% | -3,443.92% | -2,424.73% | 0.00% |
| Operating Income | -10.52M | -22.96M | -19.06M | -19.88M | -19.73M | -10.33M | -5.69M |
| Operating Income Ratio | -2,439.47% | -1,771.99% | -1,236.31% | -2,180.86% | -3,686.76% | -2,693.47% | 0.00% |
| Total Other Income/Expenses | 6.18M | 6.06M | -7.91M | 25.20M | -1.92M | -4.81M | 3.13M |
| Income Before Tax | -4.34M | -11.53M | -27.11M | 4.92M | -20.12M | -15.13M | -2.56M |
| Income Before Tax Ratio | -1,006.30% | -889.36% | -1,758.64% | 539.78% | -3,759.01% | -3,946.93% | 0.00% |
| Income Tax Expense | 0.00 | -6.21M | -1.83M | -1.51M | 737.64K | -302.76K | -14.05K |
| Net Income | -2.82M | -5.31M | -25.29M | 7.07M | -20.85M | -14.83M | -2.55M |
| Net Income Ratio | -654.80% | -410.10% | -1,640.21% | 775.29% | -3,896.84% | -3,867.97% | 0.00% |
| EPS | -0.62 | -14.89 | -7.22 | 2.03 | -7.19 | -5.31 | -0.85 |
| EPS Diluted | -0.62 | -14.89 | -7.22 | 2.00 | -7.19 | -5.31 | -0.85 |
| Weighted Avg Shares Out | 4.52M | 356.95K | 3.50M | 3.11M | 2.90M | 2.79M | 3.01M |
| Weighted Avg Shares Out (Dil) | 4.52M | 356.95K | 3.50M | 3.15M | 2.90M | 2.79M | 3.01M |
Aptorum To Start Testing SACT-1 In Neuroblastoma Patients
Aptorum Group Announces Further Positive Interim Results of the Phase 1 Clinical Trial of ALS-4 Targeting Staphylococcus aureus
3 Penny Stocks on Reddit Making Big Waves Right Now
APM Stock: Over 4% Increase Pre-Market Explanation
APM Stock: 9 Things to Know About Aptorum as Shares Fly on Staph Infection Drug News
APM Stock Price Increases Over 64% Pre-Market: Why It Happened
Aptorum Group Receives Clearance from Health Canada to Initiate a Phase 1 Clinical Trial for ALS-4, a Small Molecule Drug for Infections Caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)
Aptorum Group Announces Submission of Clinical Trial Application for ALS-4, an Orally Administered Small Molecule Drug for the Treatment of Infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)
Aptorum Group Limited 2020 Q2 - Results - Earnings Call Presentation
New APM Study Reveals the Contribution of Projects and Project Management in the Health, Pharmaceutical and Life Sciences Sector
Source: https://incomestatements.info
Category: Stock Reports